Kyowa Kirin Co., Ltd. (KYKOF)

Market Cap	8.39B +1.3%
Revenue (ttm)	3.39B +10.4%
Net Income	547.97M +135.5%
EPS	1.04 +135.5%
Shares Out	n/a
PE Ratio	15.67
Forward PE	n/a
Dividend	0.44 (2.68%)
Ex-Dividend Date	Dec 29, 2026

Volume	500
Open	16.31
Previous Close	16.13
Day's Range	16.31 - 16.31
52-Week Range	4.20 - 18.00
Beta	0.22
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 2, 2026

About Kyowa Kirin

Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, and marketing of pharmaceuticals in Japan, the Americas, Europe, Asia, and internationally. The company offers Ziftomenib, an oral menin inhibitor for the treatment of adult relapsed or refractory and acute myeloid leukemia with a nucelophosmin1 mutation; and Lumicef for the treatment of palmoplantar pustulosis. It also develops KHK4083/AMG 451 rocatinlimab, which is in Phase III clinical trial for the treatment of moderate to severe atopic dermatitis and prurigo nodular...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1949
• Employees: 5,161
• Stock Exchange: OTCMKTS
• Ticker Symbol: KYKOF

Financial Performance

In 2025, Kyowa Kirin's revenue was 496.83 billion, an increase of 0.26% compared to the previous year's 495.56 billion. Earnings were 67.04 billion, an increase of 11.98%.

Financial numbers in JPY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 9, 2026

Data Sources Report a data error